Small-cell neuroendocrine prostate cancer (SCNPC) is an aggressive variant form of prostate cancer that is resistant to androgen receptor(AR)-directed targeted therapies. SCNPC has molecular and morphological features in common with other aggressive small-cell tumors such as small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC). We recently conducted a pan-cancer transcriptomic analysis to identify “druggable” targets that display conserved expression patterns across small-cell tumors. Using this method, we identified and subsequently determined that BCL2 inhibitors (BCL2i) are lethal in SCNPC cell lines and repress the growth of a subset of SCNPC patient-derived xenograft models (PDXs). In this study, we profile the expression of an additional candidate target identified by this method, L1CAM.